Trial Watch: Dendritic cell-based interventions for cancer therapy

Erika Vacchelli, Ilio Vitale, Alexander Eggermont, Wolf Hervé Fridman, Jitka Fučíková, Isabelle Cremer, Jérôme Galon, Eric Tartour, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Research output: Contribution to journalArticlepeer-review

Abstract

Dendritic cells (DCs) occupy a privileged position at the interface between innate and adaptive immunity, orchestrating a large panel of responses to both physiological and pathological cues. In particular, whereas the presentation of antigens by immature DCs generally results in the development of immunological tolerance, mature DCs are capable of priming robust, and hence therapeutically relevant, adaptive immune responses. In line with this notion, functional defects in the DC compartment have been shown to etiologically contribute to pathological conditions including (but perhaps not limited to) infectious diseases, allergic and autoimmune disorders, graft rejection and cancer. Thus, the possibility of harnessing the elevated immunological potential of DCs for anticancer therapy has attracted considerable interest from both researchers and clinicians over the last decade. Alongside, several methods have been developed not only to isolate DCs from cancer patients, expand them, load them with tumorassociated antigens and hence generate highly immunogenic clinical grade infusion products, but also to directly target DCs in vivo. This intense experimental effort has culminated in 2010 with the approval by the US FDA of a DC-based preparation (sipuleucel-T, Provenge®) for the treatment of asymptomatic or minimally symptomatic metastatic castration-refractory prostate cancer. As an update to the latest Trial Watch dealing with this exciting field of research (October 2012), here we summarize recent advances in DC-based anticancer regimens, covering both high-impact studies that have been published during the last 13 mo and clinical trials that have been launched in the same period to assess the antineoplastic potential of this variant of cellular immunotherapy

Original languageEnglish
Article numbere25771
JournalOncoImmunology
Volume2
Issue number10
DOIs
Publication statusPublished - 2013

Keywords

  • Antigen-presenting cells
  • Immunogenic cell death
  • Monoclonal antibodies
  • Plasmacytoid dendritic cells
  • Regulatory T cells
  • Toll-like receptors

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Fingerprint Dive into the research topics of 'Trial Watch: Dendritic cell-based interventions for cancer therapy'. Together they form a unique fingerprint.

Cite this